We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Research Lab to Develop World’s First Neural Device to Restore Memory

By LabMedica International staff writers
Posted on 04 Aug 2014
Print article
Image: Lawrence Livermore National Laboratory (LLNL) will develop an implantable neural device with the ability to record and stimulate neurons within the brain to help restore memory (Photo courtesy of DOE/Lawrence Livermore National Laboratory).
Image: Lawrence Livermore National Laboratory (LLNL) will develop an implantable neural device with the ability to record and stimulate neurons within the brain to help restore memory (Photo courtesy of DOE/Lawrence Livermore National Laboratory).
A USD 2.5 million grant has been awarded to a US research lab to develop an implantable neural device with the ability to record and stimulate neurons within the brain to help restore memory.

The US Department of Defense’s Defense Advanced Research Projects Agency (DARPA) awarded the grant to Lawrence Livermore National Laboratory (LLNL; Livermore, CA, USA). The research builds on the knowledge that memory is a process in which neurons in specific regions of the brain encode information, store it, and retrieve it. Specific types of disorders and injuries, including traumatic brain injury (TBI), Alzheimer’s disease, and epilepsy, disrupt this process and cause memory loss. TBI, specifically, has affected 270,000 military service members since 2000.

The objective of LLNL’s research initiated by LLNL’s Neural Technology group and undertaken in collaboration with the University of California, Los Angeles (UCLA; USA) and Medtronic (Minneapolis, MN, USA) is to develop a device that uses real-time recording and closed-loop stimulation of neural tissues to bridge gaps in the injured brain and restore individuals’ ability to form new memories and access previously formed ones.

The research is funded by DARPA’s Restoring Active Memory (RAM) program. Specifically, the neural technology group are trying to develop a neuromodulation system, an advanced electronics system to modulate neurons, which will investigate areas of the brain associated with memory to understand how new memories are formed. The device will be developed at LLNL’s Center for Bioengineering.

“Currently, there is no effective treatment for memory loss resulting from conditions like TBI,” said LLNL’s project leader Dr. Satinderpall Pannu, director of the LLNL’s Center for Bioengineering, a unique facility dedicated to fabricating biocompatible neural interfaces. “This is a tremendous opportunity from DARPA to leverage Lawrence Livermore’s advanced capabilities to develop cutting-edge medical devices that will change the health care landscape.”

LLNL engineers will devise a miniature, wireless and chronically implantable neural device that will incorporate both single neuron and local field potential recordings into a closed-loop system to implant into TBI patients’ brains. The device implanted into the entorhinal cortex and hippocampus will allow for stimulation and recording from 64 channels located on two high-density electrode arrays. The entorhinal cortex and hippocampus are brain regions associated with memory.

The arrays will connect to an implantable electronics bundle capable of wireless data and power telemetry. An external electronic system worn around the ear will store digital information associated with memory storage and retrieval and provide power telemetry to the implantable package using a custom radiofrequency (RF) coil system.

The device’s electrodes will be integrated with electronics using advanced LLNL integration and 3D packaging technologies, and are designed to last throughout the duration of treatment. The microelectrodes that are the heart of this device are embedded in a biocompatible, flexible polymer. Using the Center for Bioengineering’s capabilities, Dr. Pannu and his team of engineers have achieved 25 patents and many publications during the last 10 years. The team's goal is to build the new prototype device for clinical testing by 2017.

Lawrence Livermore’s collaborators, UCLA and Medtronic, will focus on conducting clinical trials and creating parts and components, respectively. “The RAM program poses a formidable challenge reaching across multiple disciplines from basic brain research to medicine, computing and engineering,” said Itzhak Fried, lead investigator for the UCLA on this project and professor of neurosurgery and psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA and the Semel Institute for Neuroscience and Human Behavior. “But at the end of the day, it is the suffering individual, whether an injured member of the armed forces or a patient with Alzheimer’s disease, who is at the center of our thoughts and efforts.”

LLNL’s work on the Restoring Active Memory program supports President Obama’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative. “Our years of experience developing implantable microdevices, through projects funded by the Department of Energy [DOE], prepared us to respond to DARPA’s challenge,” said Lawrence Livermore engineer Kedar Shah, a project leader in the neural technology group.

Related Links:

Lawrence Livermore National Laboratory
University of California, Los Angeles 
Medtronic


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.